Identifying molecular markers for aggressive pituitary tumors
Molecular biomarkers of future aggressive behavior in pituitary tumors
This study is looking at the genetic changes in aggressive pituitary tumors that grow quickly after treatment, to help doctors find markers that can predict how these tumors will behave and improve treatment options for patients.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10821436 on NIH RePORTER |
What this research studies
This research investigates the genetic and epigenetic changes in pituitary adenomas that exhibit aggressive behavior, which is characterized by rapid growth after treatment. The study aims to identify specific molecular biomarkers that can predict the likelihood of these tumors becoming more aggressive, thereby helping clinicians make better treatment decisions. By analyzing patterns of chromosome variations and alterations in genes associated with tumor aggression, the research seeks to establish a foundation for improved patient management and clinical trial development.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pituitary adenomas who are at risk of aggressive tumor behavior.
Not a fit: Patients with non-aggressive pituitary tumors or those who do not have pituitary adenomas may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to better identification and treatment strategies for patients with aggressive pituitary tumors, ultimately improving their outcomes.
How similar studies have performed: While research on pituitary tumors is limited, similar approaches in identifying biomarkers for other aggressive cancers have shown promise, suggesting potential for success in this area.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Lin, Andrew — Sloan-Kettering Inst Can Research
- Study coordinator: Lin, Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.